1. Please check and comment entries here.
Table of Contents

    Topic review

    NADPH Oxidase in Glaucoma

    View times: 13
    Submitted by: Elsa Chan
    (This entry belongs to Entry Collection "Retinal Disease ")


    Glaucoma is a heterogeneous group of disorders unified by loss of retinal ganglion cells (RGCs) and their axons, resulting in a characteristic phenotype consisting of an excavated optic nerve head with corresponding visual field defects. The pathogenesis of glaucoma is incompletely understood with multiple pathophysiological factors and pathways postulated to be causative, such as mechanical, vascular, and immunological factors, leading to the final result of apoptotic death of RGCs. Increasingly it is becoming apparent that these factors do not contribute to glaucoma independently, but rather they can be viewed as a continuum in which each factor contributes to the damage of retinal ganglion cell axons.

    1. Pathogenesis of Glaucoma

    1.1. Anatomical Structure of the Optic Nerve Head and Retina

    The retina is composed of ten layers that consist of the retinal pigment epithelium as the outermost layer and the internal limiting membrane as the innermost layer. RGCs and their 1.2 to 2.0 million axons reside in the inner retina just external to the internal limiting membrane. All visual information transmitted from the retina to the brain travels through the RGC axons. These unmyelinated axons converge at the optic disc, where they exit the eye after making a 45–90° turn. The optic disc is a circular aperture in the sclera in which a multi-layered network of collagen fibres that insert into the scleral canal wall, known as the lamina cribrosa, allows passage of the axons through its pores. A complex arrangement of supportive glial tissue that consists of astrocytes, other glial cells, capillaries and extracellular matrix coats the meshwork of laminar beams that make up the lamina cribrosa. Past the lamina cribrosa, RGC axons become myelinated and terminate at the lateral geniculate nucleus and superior colliculus in the brain. These sites produce neurotrophins which are then transported in a retrograde fashion to the RGCs. As such RGC axons are critical for maintaining the health of RGCs by regulating the activity and survival of cell somas.

    The blood supply to the optic nerve is complex and unique. The central retinal artery, which enters the eye through the centre of the optic nerve, supplies blood to the inner layers of the retina and sends small branches to only the very superficial layers of the optic nerve head (ONH) [1]. The prelaminar portion of the ONH is supplied by short posterior ciliary arteries that stem off the ophthalmic artery [2][3]. These arteries form an incomplete anastomosis known as the circle of Zinn–Haler, within the scleral canal. From this circle, smaller end-arteries arise to supply the ONH, including branching capillaries that coat the lamina cribrosa. The movement of oxygen and nutrients from the laminar capillaries, through the laminar beam extracellular matrix across the astrocyte basement membrane into the astrocyte, finally reaching the peripheral and central axons of each bundle via cell processes, is critical for maintaining axonal health [4][5].

    It is likely that the ONH is the only part of the central nervous system with no blood-brain-barrier as the capillaries lack blood-brain barrier mechanisms [6]. In contrast to retinal circulation, which is highly autoregulated, the ONH circulation is less efficiently autoregulated [7], and susceptible to diffusion from the choroid circulation nearby. It is, therefore, sensitive to circulating molecules such as endothelin-1 and angiotensin II [8], which are known to cause NOX activation [9][10].

    1.2. Mechanical Theory of Glaucoma

    The mechanical theory of glaucoma offers a framework to explain the relationship between intraocular pressure-related stress and RGC pathophysiology. Elevated intraocular pressure is a well-recognised risk factor of glaucoma and the only modifiable one. Elevated intraocular pressure is the result of increased resistance in the trabecular meshwork outflow pathway, preventing adequate drainage of aqueous humour. This, in turn, impedes axoplasmic transport, resulting in apoptosis of RGCs [11]. The site of this injury is postulated to occur at the ONH, where RGC axons are more vulnerable to pressure-related changes as lamina cribrosa, being structurally weaker than sclera, is more prone to distortion and posterior-displacement [12][13]. It is the effect of this translaminar pressure gradient on axonal physiology that underpins the mechanical theory of glaucoma. Assessment of the movement of the cribrosal plates in glaucoma have demonstrated that the greatest compressive force is exerted on axons lying in the peripheral part of the optic nerve [13]; this correlates with the clinical observation that vision loss in glaucoma initiates with loss in the peripheral visual field.

    However, it is unlikely that gross deformation of the cribrosal plates occurs in the early stages of glaucoma. Whilst axons are undoubtedly damaged and lost in the early stages of glaucoma, it is not due to physical alteration of the lamina cribrosa, and its proposed mechanisms are discussed later in this article. However, stress and strain can build up at the lamina cribrosa due to elevated intraocular pressure [13][14]. Reduced lamina cribrosa elasticity with age means that in older eyes, the lamina cribrosa is less able to return to normal configuration once pressure is normalised [15]. Hence the increased prevalence of glaucoma with increasing age, and ageing is associated with oxidative stress.

    1.3. Vascular Theory of Glaucoma

    The vascular theory of glaucoma postulates that glaucoma is a consequence of insufficient blood supply to the optic nerve due to either elevated intraocular pressure or other risk factors leading to reduced ocular blood flow [16]. This results in hypoxia and ischemia to the RGC and its axons. While the question has been raised of whether reduced ocular blood flow may, in fact, be a consequence of elevated intraocular pressure in glaucoma, rather a cause [17], investigators argue that evidence direct us to reduced ocular blood flow as a cause for these reasons: Firstly, effects of reduced ocular blood flow is often more pronounced in those with normal tension glaucoma rather than high-tension glaucoma, such as optic disc haemorrhages [18][19]. Secondly, reduced ocular blood flow is often not confined to the eye alone but often seen beyond the eye [20]. Finally, reduced blood flow precedes glaucomatous disease in at least some patients [21]. There are also many clinical indications of this being the underlying pathophysiology, both within the eye and systemically. Optic disc haemorrhages are one of the hallmarks of glaucoma, especially poorly-controlled glaucoma [18][22]. Increased risk of venous thrombosis [23][24]; and vasoconstriction of the retina [25] are also more frequently seen in patients with glaucoma. Systemically, there is an association between cardiovascular disease and the development of glaucoma. Specific risk factors include systemic hypertension [26][27] or hypotension [28][29][30], a previous haemodynamic crisis [31][32], diabetes [33][34], and increased blood viscosity [35]. Migraines [36][37], Raynaud’s phenomenon [38][39], and other conditions related to vasospasm have also been identified as risk factors for the development of normal tension glaucoma [36][39][40]. In this review, we will focus on the role of NOX-dependent oxidative stress in the eye. However, it is well known that NOX-dependent oxidative stress is implicated in cardiovascular diseases [40]. Impaired endothelial cell function has been described in glaucoma patients [41], as well as increased blood plasma and aqueous humour levels of endothelin-1 [42][43][44], although this finding is not specific to glaucoma patients alone [45].

    The exact underlying cause of impaired ocular blood flow still unknown, and a detailed analysis is beyond the scope of this article. However, three potential causes have been suggested: (1) increased resistance to flow such as with arteriosclerosis; (2) reduced perfusion pressure, such as seen in systemic hypotension or primary vasospastic syndrome; (3) increased blood viscosity. The dependence of the ONH on end-arteries to deliver its vascular supply likely predisposes this risk. While we do not yet have a treatment that directly targets reduced ocular blood flow to treat glaucoma, the lowering of intraocular pressure, which is the only currently available treatment strategy, may in part work by increasing blood flow [17].

    1.4. Immunological Theory of Glaucoma

    As with all cell types, homeostasis and survival of RGCs depend on a well-functioning immune system. As glaucoma is frequently considered a neurodegenerative disease, it is perhaps not surprising that processes associated with impairment of the immune system seen in other central nervous system (CNS) diseases are also identified in glaucoma [46]. The idea that glaucoma is associated with impaired immunity was first raised by Wax in 1998 when he described antibodies against endogenous antigens such as heat shock proteins (HSP) in the serum of glaucoma patients [47]. HSPs are important for cellular defence and are upregulated during pathophysiological conditions. Since then, activity associated with both innate and adaptive immunity has been described in glaucoma [48][49][50].

    Microglial cells are specialised macrophages of the CNS. They are in the frontline of active immune defence and act as scavengers to clear the debris of dead or dying neurons. However, they can also have a destructive role and can harm the cells by releasing cytokines such as tumour necrosis factor (TNFα) and may play a role in the initiation of RGC death [51]. Microglia have been shown to be activated by elevated intraocular pressure in experimental models of glaucoma [52].

    Monocytes have been reported to mediate axonal damage in mouse models of glaucoma and inhibition of this activity have been demonstrated to have a protective effect [53]. This is likely to be associated with activation of a leukocyte transendothelial migration pathway which allows proinflammatory cytokines to enter the ONH. Howell et al. [54] subsequently demonstrated that localised radiation of the ONH could be neuroprotective by reducing the activation of optic nerve microglia.

    2. Oxidative Stress in Glaucoma

    Oxidative stress in its simplest form refers to the imbalance of free radicals and antioxidants in the body that can result in tissue damage. Reactive oxygen species (ROS) are a major source of oxidative stress, and they include free radicals such as superoxide anion (O2), hydroxyl radical, lipid radical and nitric oxide (NO). Uncontrolled production of ROS can lead to cell damage, necrosis or apoptosis via oxidation of macromolecules such as proteins [55][56], lipids [57], nuclear DNA [58], or mitochondrial DNA [59]. Oxidative stress is recognised to be an important mechanism of cell death in neurodegenerative diseases, including glaucoma [60]. While there are numerous enzyme systems that produce ROS in mammalian cells, four enzyme systems predominate; these include NADPH oxidase [61], xanthine oxidase [62], uncoupled NO synthase [63], and the mitochondrial electron transport chain [64].

    Our understanding of the role of oxidative stress generated by the mitochondrial electron transport chain is more profound than the other enzymatic systems because in recent years considerable research has been conducted on the bioenergetic processes of RGC axons [65][66][67], whereas little is known about oxidative stress related to NO synthase and xanthine oxidase in glaucoma. The oxygen consumption of RGCs is immensely high: each RGC consumes 4.68 × 108 ATP molecules/s to prevent complete loss of vision [66]. This is about 5-fold greater than the requirement of mammalian photoreceptors in darkness and similar to the requirement of unmyelinated hippocampal axons (mossy fibres) to maintain action potentials. This high energy expenditure is largely consumed by the generating of action potentials and re-establishing the resting membrane potential [68]. RGCs are able to maintain this considerable energy demand due to the abundance of mitochondria present throughout the cell soma, axon and dendrites. Mitochondria concentration is highest at the lamina cribrosa, and this is consistent with their role in protecting RGCs from damage by ensuring adequate ATP supply, as the lamina cribrosa is a site vulnerable to damage [69]. Mitochondria also play an important role in maintaining synaptic integrity [70].

    3. NADPH Oxidase and Oxidative Stress

    In addition to mitochondria, NADPH oxidase, also known as the masters of the ROS producing enzymes [71], may also play an important role in the generation of ROS and oxidative stress in glaucoma. There is also evidence that mitochondrial dysfunction can activate NADPH oxidase. For instance, superoxide derived from mitochondria has been shown to induce activation of NOX2 in human lymphoblasts [72]. NADPH oxidase has been identified as one of the major sources of oxidative stress in retinal eye diseases such as ischaemic retinopathy and aged-related macular degeneration [73]. NOX-derived reactive oxygen species (ROS) regulate many cellular processes including proliferation, migration and differentiation [74]. There are seven NADPH oxidase (catalytic subunit NOX [61]) isoforms: NOX1-5 and DUOX1-2. The NOX1, NOX2, NOX4 and NOX5 are widely expressed in vascular and non-vascular cells, and they primarily produce ROS, making them unique from other redox enzymes. These isoforms have been extensively explored in cardiovascular disease, inflammation and fibrosis [73][75] and the role of NADPH oxidase in ocular diseases is still under extensive investigation. Among these isoforms, NOX1, NOX2, NOX4 are the most studied in eye pathology. NOX1 and NOX2 differ from NOX4 in the mode of activation and type of ROS produced [76]. All three isoforms have a membrane anchoring subunit p22PHOX, but the activation of both NOX1 and NOX2 requires association with their cytosolic subunits and NOX4 is constitutively active [77]. NOX1 and NOX2 generate superoxide and NOX4 mainly produce hydrogen superoxide [77] because the latter has an extracytosolic loop that facilitates the spontaneous dismutation of superoxide into hydrogen peroxide [78] (Figure 1). It has been known that the enzymatic activity of NOX can be induced by stimuli. For example, hypoxia has been shown to induce NOX1 expression and ROS production under low glucose condition to cause apoptosis in retinal ganglion cells (RGC) [79]. Proinflammatory cytokine TNFα has also been shown to cause NOX2-dependent ROS production in microglia [80] and TNFα has indeed been detected in aqueous humour of glaucoma patients [81]. HSP that is induced in glaucomatous eye [82] has also been found to regulate the enzymatic activity of NOX1 and NOX2 [83]. Accordingly, all of these stimuli are relevant to glaucoma pathology.

    Figure 1. Structural composition of fully assembled NADPH oxidase (NOX). Both NOX1 and NOX2 have a membrane anchoring subunit p22PHOX. NOX1 is associated with cytosolic subunits: NOXA1, NOXO1, Rac and NOX2 is assembled with p67PHOX, p47PHOX, p40PHOX and Rac. The catalytic domain (NOX) allows the transport of electrons (e) from cytosolic NADPH to generate O2. In contrast, NOX4 (not shown here) only has p22PHOX. NOX4 is constitutively active and primarily produces hydrogen peroxide.

    Recently advanced glycation end products (AGEs) that are formed as a result of glycation of proteins and lipids have also been implicated in the pathology of age-related eye diseases such as glaucoma [84][85]. Indeed, restoring the function of AGEs detoxifying enzyme glyoxalase (GLO) has been shown to prevent diabetic retinopathy injury [86]. While AGEs are sources of oxidative stress, the generated oxidant products have been known to promote the formation of AGEs, thus providing a positive feedback mechanism to enhance oxidative stress [84]. Apart from AGEs, NADPH oxidase-derived ROS have also shown to accelerate the synthesis of AGEs. Although it is not the focus of the present review, a correlation in the context of oxidative stress has been proposed among AGEs, NADPH oxidase and mitochondria [87].

    4. Expression of NADPH Oxidase and Glaucoma Pathology

    Several animal models of glaucoma have been used to characterise the expression of NADPH oxidase in the pathogenesis of glaucoma. The animal models utilise different techniques to mimic various pathological processes in glaucoma, such as retinal ischemia and reperfusion, ocular hypertension, and optic nerve crush injury, to mimic pathological features of glaucoma [88]. Some features, including microglial activation and neuronal injury in the retina, and neuronal cell death due to apoptosis of RGC in glaucoma, can lead to vision impairment [89]. Here we describe the relationship between NOX expression and pathological features in the animal models of glaucoma.

    4.1. Retinal Ischemia and Reperfusion

    By applying a transient period of ischemia to the retina to induce neuronal cell injury in mice, Yokota et al. characterised the relationship of NOX expression in neuronal cell death and glial cell activation in ischaemic/reperfused retinas [90]. While the mRNA of NOX1, NOX2, NOX3, NOX4 and NOX cytosolic subunits p22PHOX and p47PHOX is detected in the non-ischaemic mouse retinas, only gene expression of both NOX2 and p22PHOX is induced after ischemia and reperfusion [90]. Furthermore, Yokota et al. [90] used NOX2-deficient mice to verify that NOX2-dependent ROS generation is localised to the inner retina, and NOX2 deletion can prevent both the apoptosis of neurons in the RGC layer and activation of glia after ischemia and reperfusion. In contrast, Dvoriantchikova et al. [79] showed that ischemia and reperfusion enhanced the immunostaining of both NOX1 and its regulatory subunit NOXO1 in the RGC layer without affecting NOX2, NOX4 and p47PHOX in mice. The variations in the time of ischemia and reperfusion or detection methods may account for the discrepancies between the two studies. Although both studies subjected the retinas to forty to sixty minutes of ischemia, the reperfusion duration was different [79][90]. It should be noted that Yokota et al. [90] used Western blotting to analyse the overall expression of NOX2 in the retinas and showed that NOX2 induction commences at three hours and peaks at six and twelve hours after ischemia and reperfusion [90]. On the other hand, Dvoriantchikova et al. used immunofluorescence to determine the tissue distribution of NOX expression in retinal sections from mice following three hours of retinal ischemia and reperfusion [79]. The two study outcomes also reflect the distinct activation of NOX isoforms in different layers of the retina upon ischemic challenge, for example, NOX1 is mainly induced in the RGC layer where it contributes to the death of RGC [79] and NOX2 is distributed throughout the inner retina [90] where it promotes glial cell activation as well as RGC apoptosis. Hence inhibiting NOX activation may prevent neuronal cell damages resulting from the ischaemic insult that occurs in acute glaucoma.

    4.2. Ocular Hypertension

    Ocular hypertension in animals is induced by either applying laser photocoagulation to the trabecular meshwork or cauterizing the episcleral vein [88]. NOX2 has been found to co-localise with activated microglia in the ONHs from mice after laser photocoagulation of the trabecular meshwork [65]. It is proposed that the ROS produced from the microglial NOX2 cause a disruption to the axonal transport in these mice following laser photocoagulation to the trabecular meshwork [65]. In a model of unilateral ocular hypertension induced by episcleral vein cauterization, ocular hypertension causes activation of both astrocytes and microglia in retinas, and this is accompanied by an induction of NOX2 mRNA [91], supporting a role of NOX2 in retinal inflammation. Although the expression of NOX2 is assessed in the two models of ocular hypertension, the interaction between NOX2 and microglial activation has not been investigated [65][91]. Interestingly, NOX2 in microglia is thought to promote the polarization of microglia to the M1-like phenotype in mice brain after traumatic brain injury because the deletion of NOX2 gene reduces M1-like activation but induces the activation of M2-like phenotype in the injured brain [92]. M1-like phenotype is known to be involved in inflammatory response while M2-like microglia facilitates tissue repair by suppressing injury-induced inflammation and re-establishing tissue homeostasis [93]. The demonstration of NOX2 in polarizing microglia to M1-phenotype after brain injury reflects a major role of NOX2 in neuroinflammation. Moreover, NOX2-dependent ROS signalling can promote leukocyte transendothelial migration [94], a process that is known to allow proinflammatory cytokines to enter the ONH during inflammation. Apart from the degeneration of RGC, neuroinflammation also contributes to the progression of glaucoma [81]. Hence, these data provide some insights into how NOX2 may facilitate the initiation and propagation of inflammation. Because microglial activation can induce or amplify the damages to RGC in glaucoma [95], it will be of great interest to elucidate whether NOX2 also affects the polarisation of microglia or leukocyte transendothelial migration in animal models of glaucoma. Apart from its association with activated microglia, NOX2 expression has also been found in retinal arterioles of mice with ocular hypertension [96]. The mRNA level of NOX2 but not NOX1 is upregulated in retinas with ocular hypertension, and it is thought that NOX2-dependent ROS production is involved in the reduced endothelium-dependent relaxation of retinal blood vessels in the presence of ocular hypertension [96]. In a comparable microvascular network to the eye such as the cerebrum, NOX2 is also involved in the angiotensin II-induced endothelial dysfunction [97], and angiotensin II is known to cause hypertension [98]. The findings thus highlight the role of NOX2 in endothelial dysfunction induced by hypertension.

    4.3. Optic Nerve Injury

    Optic nerve crush is another experimental approach that induces neuronal cell damage in the retina [99]. Mice with optic nerve crush injury demonstrated RGC death as well as increases in mRNA expression of NOX1, NOX2 and NOX4 in the retina [100]In situ detection of ROS also confirmed that the retinal ganglion layer is the primary site of ROS production in these mice [100]. Since ROS are short-lived, RGC layer presumably harbours the identified ROS generating enzymes NOX1, NOX2 and NOX4, which promote RGC death through ROS production after optic nerve crush injury [100]. In a rat model of nonarteritic anterior ischemic optic neuropathy where the optic nerve was injured with laser, it was thought that NOX2 induction is involved in the microglial activation in the anterior optic nerve [101].

    Accumulating findings from animal models of glaucoma revealed that NOX induction is involved in the progression of glaucoma (Table 1); however, the expression profile of NOX in human eyes is very scarce, and this is largely due to very limited tissue sources. The demonstration of NOX2 and NOX4 induction in alkali-burnt eye sections from a patient is one of the few investigations that characterises NOX expression in human corneal specimen [102]. Another assessment of NOX in clinical samples comes from the profiling of NOX4 protein expression in different grades of excised ocular tumours and, NOX4 expression is found to be correlated to higher grade retinoblastoma and massive choroidal invasion [103]. The profiling of NOX expression in clinical samples from glaucoma patients is yet to be explored.

    Table 1. Summary of NOX expression in animal models of glaucoma.

    The entry is from 10.3390/antiox10020238


    1. Olver, J. Angioarchitecture of the Human Optic Nerve; Innovation-News-Communication: Rome, Italy, 1998.
    2. Hayreh, S.S. Blood supply of the optic nerve head. Ophthalmologica 1996, 210, 285–295.
    3. Hayreh, S.S. Blood flow in the optic nerve head and factors that may influence it. Prog. Retin. Eye Res. 2001, 20, 595–624.
    4. Anderson, D.R. Ultrastructure of human and monkey lamina cribrosa and optic nerve head. Arch. Ophthalmol. 1969, 82, 800–814.
    5. Hernandez, M.R. The optic nerve head in glaucoma: Role of astrocytes in tissue remodeling. Prog. Retin. Eye Res. 2000, 19, 297–321.
    6. Hofman, P.; Hoyng, P.; vanderWerf, F.; Vrensen, G.F.; Schlingemann, R.O. Lack of blood-brain barrier properties in microvessels of the prelaminar optic nerve head. Investig. Ophthalmol. Vis. Sci. 2001, 42, 895–901.
    7. Pournaras, C.J.; Riva, C.E. Studies of the hemodynamics of the optic head nerve using laser Doppler flowmetry. J. Français Ophtalmol. 2001, 24, 199–205.
    8. Flammer, J.; Orgul, S. Optic nerve blood-flow abnormalities in glaucoma. Prog. Retin. Eye Res. 1998, 17, 267–289.
    9. Montezano, A.C.; Nguyen Dinh Cat, A.; Rios, F.J.; Touyz, R.M. Angiotensin II and vascular injury. Curr. Hypertens. Rep. 2014, 16, 431.
    10. Wilkinson-Berka, J.L.; Tan, G.; Jaworski, K.; Harbig, J.; Miller, A.G. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ. Res. 2009, 104, 124–133.
    11. Moreno, M.C.; Campanelli, J.; Sande, P.; Sanez, D.A.; Keller Sarmiento, M.I.; Rosenstein, R.E. Retinal oxidative stress induced by high intraocular pressure. Free Radic. Biol. Med. 2004, 37, 803–812.
    12. Quigley, H.A.; Addicks, E.M. Regional differences in the structure of the lamina cribrosa and their relation to glaucomatous optic nerve damage. Arch. Ophthalmol. 1981, 99, 137–143.
    13. Burgoyne, C.F.; Downs, J.C.; Bellezza, A.J.; Suh, J.K.; Hart, R.T. The optic nerve head as a biomechanical structure: A new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog. Retin. Eye Res. 2005, 24, 39–73.
    14. Burgoyne, C.F.; Downs, J.C.; Bellezza, A.J.; Hart, R.T. Three-dimensional reconstruction of normal and early glaucoma monkey optic nerve head connective tissues. Investig. Ophthalmol. Vis. Sci. 2004, 45, 4388–4399.
    15. Albon, J.; Purslow, P.P.; Karwatowski, W.S.; Easty, D.L. Age related compliance of the lamina cribrosa in human eyes. Br. J. Ophthalmol. 2000, 84, 318–323.
    16. Flammer, J. The vascular concept of glaucoma. Surv. Ophthalmol. 1994, 38, S3–S6.
    17. Flammer, J.; Orgul, S.; Costa, V.P.; Orzalesi, N.; Krieglstein, G.K.; Serra, L.M.; Renard, J.P.; Stefansson, E. The impact of ocular blood flow in glaucoma. Prog. Retin. Eye Res. 2002, 21, 359–393.
    18. Drance, S.; Anderson, D.R.; Schulzer, M.; Collaborative Normal-Tension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am. J. Ophthalmol. 2001, 131, 699–708.
    19. Healey, P.R.; Mitchell, P.; Smith, W.; Wang, J.J. Optic disc hemorrhages in a population with and without signs of glaucoma. Ophthalmology 1998, 105, 216–223.
    20. Gasser, P.; Flammer, J. Blood-cell velocity in the nailfold capillaries of patients with normal-tension and high-tension glaucoma. Am. J. Ophthalmol. 1991, 111, 585–588.
    21. Nicolela, M.T.; Walman, B.E.; Buckley, A.R.; Drance, S.M. Ocular hypertension and primary open-angle glaucoma: A comparative study of their retrobulbar blood flow velocity. J. Glaucoma 1996, 5, 308–310.
    22. Siegner, S.W.; Netland, P.A. Optic disc hemorrhages and progression of glaucoma. Ophthalmology 1996, 103, 1014–1024.
    23. Klein, R.; Klein, B.E.; Moss, S.E.; Meuer, S.M. The epidemiology of retinal vein occlusion: The Beaver Dam Eye Study. Trans. Am. Ophthalmol. Soc. 2000, 98, 133–141.
    24. Sonnsjo, B.; Krakau, C.E. Arguments for a vascular glaucoma etiology. Acta Ophthalmol. 1993, 71, 433–444.
    25. Rankin, S.J.; Drance, S.M. Peripapillary focal retinal arteriolar narrowing in open angle glaucoma. J. Glaucoma 1996, 5, 22–28.
    26. Zhao, D.; Cho, J.; Kim, M.H.; Guallar, E. The association of blood pressure and primary open-angle glaucoma: A meta-analysis. Am. J. Ophthalmol. 2014, 158, 615–627.e619.
    27. Levine, R.M.; Yang, A.; Brahma, V.; Martone, J.F. Management of Blood Pressure in Patients with Glaucoma. Curr. Cardiol. Rep. 2017, 19, 109.
    28. De Moraes, C.G.; Cioffi, G.A.; Weinreb, R.N.; Liebmann, J.M. New Recommendations for the Treatment of Systemic Hypertension and their Potential Implications for Glaucoma Management. J. Glaucoma 2018, 27, 567–571.
    29. Schmidl, D.; Garhofer, G.; Schmetterer, L. The complex interaction between ocular perfusion pressure and ocular blood flow - relevance for glaucoma. Exp. Eye Res. 2011, 93, 141–155.
    30. Skrzypecki, J.; Ufnal, M.; Szaflik, J.P.; Filipiak, K.J. Blood pressure and glaucoma: At the crossroads between cardiology and ophthalmology. Cardiol. J. 2019, 26, 8–12.
    31. Morgan, R.W.; Drance, S.M. Chronic open-angle glaucoma and ocular hypertension. An epidemiological study. Br. J. Ophthalmol. 1975, 59, 211–215.
    32. Drance, S.M.; Sweeney, V.P.; Morgan, R.W.; Feldman, F. Studies of factors involved in the production of low tension glaucoma. Arch. Ophthalmol 1973, 89, 457–465.
    33. Song, B.J.; Aiello, L.P.; Pasquale, L.R. Presence and Risk Factors for Glaucoma in Patients with Diabetes. Curr. Diab. Rep. 2016, 16, 124.
    34. Gerber, A.L.; Harris, A.; Siesky, B.; Lee, E.; Schaab, T.J.; Huck, A.; Amireskandari, A. Vascular Dysfunction in Diabetes and Glaucoma: A Complex Relationship Reviewed. J. Glaucoma 2015, 24, 474–479.
    35. Trope, G.E.; Salinas, R.G.; Glynn, M. Blood viscosity in primary open-angle glaucoma. Can. J. Ophthalmol. 1987, 22, 202–204.
    36. Gramer, G.; Weber, B.H.; Gramer, E. Migraine and Vasospasm in Glaucoma: Age-Related Evaluation of 2027 Patients With Glaucoma or Ocular Hypertension. Investig. Opthalmol. Vis. Sci. 2015, 56, 7999–8007.
    37. Huang, J.Y.; Su, C.C.; Wang, T.H.; Tsai, I.J. Migraine and increased risk of developing open angle glaucoma: A population-based cohort study. BMC Ophthalmol 2019, 19, 50.
    38. Konieczka, K.; Choi, H.J.; Koch, S.; Fankhauser, F.; Schoetzau, A.; Kim, D.M. Relationship between normal tension glaucoma and Flammer syndrome. EPMA J. 2017, 8, 111–117.
    39. Nicolela, M.T.; Ferrier, S.N.; Morrison, C.A.; Archibald, M.L.; LeVatte, T.L.; Wallace, K.; Chauhan, B.C.; LeBlanc, R.P. Effects of cold-induced vasospasm in glaucoma: The role of endothelin-1. Investig. Opthalmol. Vis. Sci. 2003, 44, 2565–2572.
    40. Zhang, Y.; Murugesan, P.; Huang, K.; Cai, H. NADPH oxidases and oxidase crosstalk in cardiovascular diseases: Novel therapeutic targets. Nat. Rev. Cardiol. 2020, 17, 170–194.
    41. Henry, E.; Newby, D.E.; Webb, D.J.; O’Brien, C. Peripheral endothelial dysfunction in normal pressure glaucoma. Investig. Ophthalmol. Vis. Sci. 1999, 40, 1710–1714.
    42. Sugiyama, T.; Moriya, S.; Oku, H.; Azuma, I. Association of endothelin-1 with normal tension glaucoma: Clinical and fundamental studies. Surv. Ophthalmol. 1995, 39 (Suppl. S1), S49–S56.
    43. Kaiser, H.J.; Flammer, J.; Wenk, M.; Luscher, T. Endothelin-1 plasma levels in normal-tension glaucoma: Abnormal response to postural changes. Graefes Arch. Clin. Exp. Ophthalmol. 1995, 233, 484–488.
    44. Noske, W.; Hensen, J.; Wiederholt, M. Endothelin-like immunoreactivity in aqueous humor of patients with primary open-angle glaucoma and cataract. Graefes Arch. Clin. Exp. Ophthalmol. 1997, 235, 551–552.
    45. Haufschild, T.; Shaw, S.G.; Kesselring, J.; Flammer, J. Increased endothelin-1 plasma levels in patients with multiple sclerosis. J. Neuroophthalmol. 2001, 21, 37–38.
    46. Sofroniew, M.V.; Vinters, H.V. Astrocytes: Biology and pathology. Acta Neuropathol. 2010, 119, 7–35.
    47. Wax, M.B.; Tezel, G.; Saito, I.; Gupta, R.S.; Harley, J.B.; Li, Z.; Romano, C. Anti-Ro/SS-A positivity and heat shock protein antibodies in patients with normal-pressure glaucoma. Am. J. Ophthalmol. 1998, 125, 145–157.
    48. Tezel, G.; Wax, M.B. Glaucoma. Chem. Immunol. Allergy 2007, 92, 221–227.
    49. Wax, M.B.; Tezel, G. Immunoregulation of retinal ganglion cell fate in glaucoma. Exp. Eye Res. 2009, 88, 825–830.
    50. Tezel, G. Fourth, ARVO/Pfizer Ophthalmics Research Institute Conference Working Group, and the immune system in glaucoma. Investig. Ophthalmol. Vis. Sci. 2009, 50, 1001–1012.
    51. Neufeld, A.H. Microglia in the optic nerve head and the region of parapapillary chorioretinal atrophy in glaucoma. Arch. Ophthalmol. 1999, 117, 1050–1056.
    52. Ju, K.R.; Kim, H.S.; Kim, J.H.; Lee, N.Y.; Park, C.K. Retinal glial cell responses and Fas/FasL activation in rats with chronic ocular hypertension. Brain Res. 2006, 1122, 209–221.
    53. Bosco, A.; Steele, M.R.; Vetter, M.L. Early microglia activation in a mouse model of chronic glaucoma. J. Comp. Neurol. 2011, 519, 599–620.
    54. Howell, G.R.; Soto, I.; Zhu, X.; Ryan, M.; Macalinao, D.G.; Sousa, G.L.; Caddle, L.B.; MacNicoll, K.H.; Barbay, J.M.; Porciatti, V.; et al. Radiation treatment inhibits monocyte entry into the optic nerve head and prevents neuronal damage in a mouse model of glaucoma. J. Clin. Investig. 2012, 122, 1246–1261.
    55. Butterfield, D.A.; Howard, B.J.; Yatin, S.; Allen, K.L.; Carney, J.M. Free radical oxidation of brain proteins in accelerated senescence and its modulation by N-tert-butyl-alpha-phenylnitrone. Proc. Natl. Acad. Sci. USA 1997, 94, 674–678.
    56. Cakatay, U.; Telci, A.; Kayali, R.; Tekeli, F.; Akcay, T.; Sivas, A. Relation of oxidative protein damage and nitrotyrosine levels in the aging rat brain. Exp. Gerontol. 2001, 36, 221–229.
    57. Papaioannou, N.; Tooten, P.C.; van Ederen, A.M.; Bohl, J.R.; Rofina, J.; Tsangaris, T.; Gruys, E. Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques. Amyloid 2001, 8, 11–21.
    58. Sohal, R.S.; Agarwal, S.; Candas, M.; Forster, M.J.; Lal, H. Effect of age and caloric restriction on DNA oxidative damage in different tissues of C57BL/6 mice. Mech. Ageing Dev. 1994, 76, 215–224.
    59. Jarrett, S.G.; Lin, H.; Godley, B.F.; Boulton, M.E. Mitochondrial DNA damage and its potential role in retinal degeneration. Prog. Retin. Eye Res. 2008, 27, 596–607.
    60. Tezel, G. Oxidative stress in glaucomatous neurodegeneration: Mechanisms and consequences. Prog. Retin. Eye Res. 2006, 25, 490–513.
    61. Griendling, K.K.; Sorescu, D.; Ushio-Fukai, M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ. Res. 2000, 86, 494–501.
    62. Spiekermann, S.; Landmesser, U.; Dikalov, S.; Bredt, M.; Gamez, G.; Tatge, H.; Reepschlager, N.; Hornig, B.; Drexler, H.; Harrison, D.G. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: Relation to endothelium-dependent vasodilation. Circulation 2003, 107, 1383–1389.
    63. Landmesser, U.; Dikalov, S.; Price, S.R.; McCann, L.; Fukai, T.; Holland, S.M.; Mitch, W.E.; Harrison, D.G. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Investig. 2003, 111, 1201–1209.
    64. Fridovich, I. Mitochondria: Are they the seat of senescence? Aging Cell 2004, 3, 13–16.
    65. Chidlow, G.; Wood, J.P.M.; Casson, R.J. Investigations into Hypoxia and Oxidative Stress at the Optic Nerve Head in a Rat Model of Glaucoma. Front. Neurosci. 2017, 11, 478.
    66. Casson, R.J.; Chidlow, G.; Wood, J.P.M. Estimate of the adenosine triphosphate requirement of human retinal ganglion cells. Clin. Exp. Ophthalmol. 2019, 47, 683–684.
    67. Lee, S.; Van Bergen, N.J.; Kong, G.Y.; Chrysostomou, V.; Waugh, H.S.; O’Neill, E.C.; Crowston, J.G.; Trounce, I.A. Mitochondrial dysfunction in glaucoma and emerging bioenergetic therapies. Exp. Eye Res. 2011, 93, 204–212.
    68. Harris, J.J.; Attwell, D. The energetics of CNS white matter. J. Neurosci. 2012, 32, 356–371.
    69. Minckler, D.S.; McLean, I.W.; Tso, M.O. Distribution of axonal and glial elements in the rhesus optic nerve head studied by electron microscopy. Am. J. Ophthalmol. 1976, 82, 179–187.
    70. Li, Z.; Okamoto, K.; Hayashi, Y.; Sheng, M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004, 119, 873–887.
    71. Ruan, Y.; Jiang, S.; Musayeva, A.; Gericke, A. Oxidative Stress and Vascular Dysfunction in the Retina: Therapeutic Strategies. Antioxidants 2020, 9, 761.
    72. Dikalov, S.I.; Li, W.; Doughan, A.K.; Blanco, R.R.; Zafari, A.M. Mitochondrial reactive oxygen species and calcium uptake regulate activation of phagocytic NADPH oxidase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 302, R1134–R1142.
    73. Chan, E.C.; Liu, G.S.; Dusting, G.J. Redox mechanisms in pathological angiogenesis in the retina: Roles for NADPH oxidase. Curr. Pharm. Des. 2015, 21, 5988–5998.
    74. Chan, E.C.; Jiang, F.; Peshavariya, H.M.; Dusting, G.J. Regulation of cell proliferation by NADPH oxidase-mediated signaling: Potential roles in tissue repair, regenerative medicine and tissue engineering. Pharmacol. Ther. 2009, 122, 97–108.
    75. Berthoud, V.M.; Beyer, E.C. Oxidative stress, lens gap junctions, and cataracts. Antioxid. Redox Signal. 2009, 11, 339–353.
    76. Magnani, F.; Mattevi, A. Structure and mechanisms of ROS generation by NADPH oxidases. Curr. Opin. Struct. Biol. 2019, 59, 91–97.
    77. Nisimoto, Y.; Diebold, B.A.; Cosentino-Gomes, D.; Lambeth, J.D. Nox4: A hydrogen peroxide-generating oxygen sensor. Biochemistry 2014, 53, 5111–5120.
    78. Takac, I.; Schroder, K.; Zhang, L.; Lardy, B.; Anilkumar, N.; Lambeth, J.D.; Shah, A.M.; Morel, F.; Brandes, R.P. The E-loop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4. J. Biol. Chem. 2011, 286, 13304–13313.
    79. Dvoriantchikova, G.; Grant, J.; Santos, A.R.; Hernandez, E.; Ivanov, D. Neuronal NAD(P)H oxidases contribute to ROS production and mediate RGC death after ischemia. Investig. Ophthalmol. Vis. Sci. 2012, 53, 2823–2830.
    80. Geng, L.; Fan, L.M.; Liu, F.; Smith, C.; Li, J. Nox2 dependent redox-regulation of microglial response to amyloid-beta stimulation and microgliosis in aging. Sci. Rep. 2020, 10, 1582.
    81. Soto, I.; Howell, G.R. The complex role of neuroinflammation in glaucoma. Cold Spring Harb. Perspect. Med. 2014, 4.
    82. Sakai, M.; Sakai, H.; Nakamura, Y.; Fukuchi, T.; Sawaguchi, S. Immunolocalization of heat shock proteins in the retina of normal monkey eyes and monkey eyes with laser-induced glaucoma. Jpn. J. Ophthalmol. 2003, 47, 42–52.
    83. Chen, F.; Pandey, D.; Chadli, A.; Catravas, J.D.; Chen, T.; Fulton, D.J. Hsp90 regulates NADPH oxidase activity and is necessary for superoxide but not hydrogen peroxide production. Antioxid. Redox Signal. 2011, 14, 2107–2119.
    84. Aragones, G.; Rowan, S.; S, G.F.; Yang, W.; Weinberg, J.; Taylor, A.; Bejarano, E. Glyoxalase System as a Therapeutic Target against Diabetic Retinopathy. Antioxidants 2020, 9, 62.
    85. Tezel, G.; Luo, C.; Yang, X. Accelerated aging in glaucoma: Immunohistochemical assessment of advanced glycation end products in the human retina and optic nerve head. Investig. Ophthalmol. Vis. Sci. 2007, 48, 1201–1211.
    86. Miller, A.G.; Tan, G.; Binger, K.J.; Pickering, R.J.; Thomas, M.C.; Nagaraj, R.H.; Cooper, M.E.; Wilkinson-Berka, J.L. Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. Diabetes 2010, 59, 3208–3215.
    87. Cepas, V.; Collino, M.; Mayo, J.C.; Sainz, R.M. Redox Signaling and Advanced Glycation Endproducts (AGEs) in Diet-Related Diseases. Antioxidants 2020, 9, 142.
    88. Evangelho, K.; Mastronardi, C.A.; de-la-Torre, A. Experimental Models of Glaucoma: A Powerful Translational Tool for the Future Development of New Therapies for Glaucoma in Humans-A Review of the Literature. Medicina 2019, 55, 280.
    89. Ramirez, A.I.; de Hoz, R.; Salobrar-Garcia, E.; Salazar, J.J.; Rojas, B.; Ajoy, D.; Lopez-Cuenca, I.; Rojas, P.; Trivino, A.; Ramirez, J.M. The Role of Microglia in Retinal Neurodegeneration: Alzheimer’s Disease, Parkinson, and Glaucoma. Front. Aging Neurosci. 2017, 9, 214.
    90. Yokota, H.; Narayanan, S.P.; Zhang, W.; Liu, H.; Rojas, M.; Xu, Z.; Lemtalsi, T.; Nagaoka, T.; Yoshida, A.; Brooks, S.E.; et al. Neuroprotection from retinal ischemia/reperfusion injury by NOX2 NADPH oxidase deletion. Investig. Ophthalmol. Vis. Sci. 2011, 52, 8123–8131.
    91. Sapienza, A.; Raveu, A.L.; Reboussin, E.; Roubeix, C.; Boucher, C.; Degardin, J.; Godefroy, D.; Rostene, W.; Reaux-Le Goazigo, A.; Baudouin, C.; et al. Bilateral neuroinflammatory processes in visual pathways induced by unilateral ocular hypertension in the rat. J. Neuroinflamm. 2016, 13, 44.
    92. Kumar, A.; Barrett, J.P.; Alvarez-Croda, D.M.; Stoica, B.A.; Faden, A.I.; Loane, D.J. NOX2 drives M1-like microglial/macrophage activation and neurodegeneration following experimental traumatic brain injury. Brain Behav. Immun. 2016, 58, 291–309.
    93. Cherry, J.D.; Olschowka, J.A.; O’Banion, M.K. Neuroinflammation and M2 microglia: The good, the bad, and the inflamed. J. Neuroinflamm. 2014, 11, 98.
    94. van Buul, J.D.; Hordijk, P.L. Signaling in leukocyte transendothelial migration. Arter. Thromb. Vasc. Biol. 2004, 24, 824–833.
    95. Rashid, K.; Akhtar-Schaefer, I.; Langmann, T. Microglia in Retinal Degeneration. Front. Immunol. 2019, 10, 1975.
    96. Gericke, A.; Mann, C.; Zadeh, J.K.; Musayeva, A.; Wolff, I.; Wang, M.; Pfeiffer, N.; Daiber, A.; Li, H.; Xia, N.; et al. Elevated Intraocular Pressure Causes Abnormal Reactivity of Mouse Retinal Arterioles. Oxid. Med. Cell. Longev. 2019, 2019, 9736047.
    97. Li, Y.; Pagano, P.J. Microvascular NADPH oxidase in health and disease. Free Radic. Biol. Med. 2017, 109, 33–47.
    98. Vital, S.A.; Terao, S.; Nagai, M.; Granger, D.N. Mechanisms underlying the cerebral microvascular responses to angiotensin II-induced hypertension. Microcirculation 2010, 17, 641–649.
    99. Tang, Z.; Zhang, S.; Lee, C.; Kumar, A.; Arjunan, P.; Li, Y.; Zhang, F.; Li, X. An optic nerve crush injury murine model to study retinal ganglion cell survival. J. Vis. Exp. 2011.
    100. Yamamoto, K.; Maruyama, K.; Himori, N.; Omodaka, K.; Yokoyama, Y.; Shiga, Y.; Morin, R.; Nakazawa, T. The novel Rho kinase (ROCK) inhibitor K-115: A new candidate drug for neuroprotective treatment in glaucoma. Investig. Ophthalmol. Vis. Sci. 2014, 55, 7126–7136.
    101. Mehrabian, Z.; Guo, Y.; Weinreich, D.; Bernstein, S.L. Oligodendrocyte death, neuroinflammation, and the effects of minocycline in a rodent model of nonarteritic anterior ischemic optic neuropathy (rNAION). Mol. Vis. 2017, 23, 963–976.
    102. Gu, X.J.; Liu, X.; Chen, Y.Y.; Zhao, Y.; Xu, M.; Han, X.J.; Liu, Q.P.; Yi, J.L.; Li, J.M. Involvement of NADPH oxidases in alkali burn-induced corneal injury. Int. J. Mol. Med. 2016, 38, 75–82.
    103. Singh, L.; Saini, N.; Pushker, N.; Sen, S.; Sharma, A.; Kashyap, S. Prognostic significance of NADPH oxidase-4 as an indicator of reactive oxygen species stress in human retinoblastoma. Int. J. Clin. Oncol. 2016, 21, 651–657.